Funding
Series B · Biotech

Exciva raises €51m Series B for Alzheimer's behavioral symptoms

EQT Life Sciences, LSP Dementia Fund, Gimv and other investors participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Exciva raised €51 million in Series B financing on January 20. Participants included EQT Life Sciences, LSP Dementia Fund, Gimv, Fountain Healthcare Partners, LifeArc, Carma Fund, Modi Ventures, Andera Partners and LBBW. The company develops therapies for behavioral symptoms associated with Alzheimer's disease.

Funding history

Series B · This round€51M

Sources

  1. Excivaprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related